Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18378114 | 0.86 | ALDH1A1 (0.31) | ALDH1A1TSHRMAPT | |
| SCHEMBL9541538 | 0.84 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL5804465 | 0.84 | GAA (0.41) | ALDH1A1TSHRMAPT | |
| SCHEMBL9860291 | 0.82 | HCAR2 (0.33) | ALDH1A1MAPT | |
| SCHEMBL11602378 | 0.82 | HTT (0.35) | HTTALDH1A1TSHR | |
| SCHEMBL9861013 | 0.82 | HCAR2 (0.33) | ALDH1A1MAPT | |
| SCHEMBL3666505 | 0.82 | TSHR (0.38) | ALDH1A1TSHRTHRB | |
| SCHEMBL6420646 | 0.81 | ALDH1A1 (0.35) | HTTALDH1A1TSHRMAPT | |
| SCHEMBL9861015 | 0.80 | HCAR2 (0.42) | ALDH1A1TSHRMAPT | |
| SCHEMBL9860300 | 0.80 | HCAR2 (0.42) | ALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| EP-3863629-A1 | PRODRUGS OF CGRP ANTAGONISTS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-112888438-A | Prodrugs of CGRP antagonists | 拜尔哈文制药股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10854451-B2 | Superplanarizing spin-on carbon materials | BREWER SCIENCE, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3311393-A1 | SUPERPLANARIZING SPIN-ON CARBON MATERIALS | Brewer Science, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20160372326-A1 | SUPERPLANARIZING SPIN-ON CARBON MATERIALS | BREWER SCIENCE INC. | 2016-12-22 | — | — | US | disclosed |
| CN-1216064-C | Process for preparing 6-o-alkenyl-substituted erythromycin derivatives | ABBOTT LAB (US) | 2005-08-24 | — | — | CN | disclosed |
| CN-1379780-A | Process for preparing 6-o-alkenyl-substituted erythromycin derivatives | ABBOTT LAB (US) | 2002-11-13 | — | — | CN | disclosed |
| WO-1993011669-A1 | USE OF 3-PHENYLURACIL DERIVATIVES FOR THE DESICCATION AND ABSCISSION OF PLANT PARTS | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | CALCRL, CALCA, CALCB | HTT 3835/4885ALDH1A1 1757/4885TSHR 1421/4885 |
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | HTT 3835/4885ALDH1A1 1757/4885TSHR 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.